Search Clinical Trials in the European Union

Duration
Visits
Efficacy phase (II)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1281-1300 of 1,738 trials

Alcohol-Associated Hepatitis: Alpha-1 Antitrypsin Treatment

We are studying whether intravenous Alpha-1 Antitrypsin can reduce inflammation in patients with severe alcohol-associated hepatitis. The trial also looks at its safety and effects on liver health.

Alcohol-Associated Hepatitis3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesHepatologyInternal Medicine

Heart Failure: CDR132L Treatment Study

We are comparing a new treatment, CDR132L, with a placebo for people with heart failure and left ventricular hypertrophy. The goal is to see if it improves heart function and structure better than standard care.

Heart Failure with Reduced Ejection Fraction6-12 monthsEfficacy phase (II)>20 visitsPartially RemoteCardiologyInternal Medicine

Vemurafenib for BRAF Positive Juvenile Histiocytosis

We are studying the safety and effectiveness of vemurafenib in children with BRAF mutation-resistant histiocytosis. This trial aims to find the best dosage and treatment duration for these young patients.

Histiocytic Cell Proliferation>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Oxybutynin for Boys with Posterior Urethral Valves

We are studying whether early treatment with oxybutynin improves bladder function in boys after surgery for posterior urethral valves. The trial also looks at the safety of the medication and its effects on urinary tract infections.

Urethral Posterior Valve>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPediatricsUrology

Tarlatamab for Advanced Small-Cell Lung Cancer

We are studying a new treatment for patients with metastatic or locally advanced small-cell lung cancer and other neuroendocrine carcinomas. The goal is to see how well it works and to understand its safety.

Metastatic Small Cell Lung Cancer>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineOncology

Brain Metastases Detection: PET-DOPA Imaging Study

We are studying a new imaging method to detect untreated brain metastases in patients with lung, breast, or melanoma cancer. This research aims to improve how we identify and understand these tumors.

Brain Metastases from Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncology

Vosoritide for Growth Issues in Children

We are studying a new treatment called vosoritide for children with Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome who haven't responded well to standard growth hormone therapy. The goal is to see if it helps improve their growth and is safe to use.

Turner SyndromeShort Stature Homeobox Gene MutationNoonan Syndrome1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyPediatrics

Biliary Tract Cancer: Ivonescimab vs. FOLFOX

We are testing a new treatment, ivonescimab, against standard chemotherapy for patients with advanced biliary tract cancer. The goal is to see if it helps patients live longer and feel better.

Advanced Biliary Tract Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Advanced Solid Tumors: 89Zr-Df-crefmirlimab Imaging Study

We are studying a new imaging method to see how well it shows cancer cells in patients with advanced solid tumors. This may help us understand treatment responses and immune cell activity better.

Metastatic Solid Tumors>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementOncology

C3 Glomerulopathy: Aliskiren vs. Enalapril

We are studying whether the medication aliskiren can improve kidney function in people with C3 glomerulopathy compared to the standard treatment, enalapril. This trial aims to assess its safety and effectiveness in reducing kidney disease markers.

C3 Glomerulopathy>2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInfectious DiseasesNephrology

Histiocytosis in Children: Trametinib Study

We are testing the safety and effectiveness of trametinib in children with refractory histiocytosis. The goal is to find the best dosage and timing for treatment after other therapies have failed.

Erdheim-Chester DiseaseRosai-Dorfman SyndromeLangerhans' Cell Histiocytosis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

Primary Biliary Cholangitis: Golexanolone Study

We are testing a new medication, golexanolone, for individuals with primary biliary cholangitis who have significant fatigue and cognitive difficulties. The study aims to evaluate its safety and effects on daily life and cognitive function.

Primary Biliary Cholangitis3-6 monthsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesHepatologyInternal Medicine

Chronic Lung Disease in Premature Babies: OHB-607 Study

We are testing a new drug to see if it helps reduce lung disease in extremely premature infants compared to standard care. The study aims to improve their overall health and development.

Chronic Lung Disease6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsPulmonology

Lung Cancer: Pembrolizumab Maintenance Study

We are studying whether continuing pembrolizumab treatment helps patients with stage IV lung cancer maintain disease control after initial chemotherapy. This trial will also look at the quality of life and side effects experienced by participants.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesOncology

Rapamycin for Drug-Resistant Epilepsy in Children

We are studying the safety and effectiveness of rapamycin for children with drug-resistant epilepsy caused by rare central nervous system diseases. This trial aims to find better treatment options for these challenging conditions.

Epilepsy and Related Disorders>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesNeurology

High-Grade Glioma in Children: Rapamycin Study

We are evaluating the safety and effectiveness of rapamycin for treating high-grade gliomas in children. This study aims to understand how well it works and if genetic factors play a role in treatment response.

High Grade Glioma>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPediatrics

DIPG Treatment: Targeted Drug Study for Children

We are testing how well certain drugs work for children with diffuse intrinsic pontine glioma (DIPG) based on their tumor's genetic makeup. The goal is to find safer and more effective treatments tailored to individual patients.

Diffuse Intrinsic Pontine Glioma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesNeurologyOncologyPediatrics

Hidradenitis Suppurativa: Brensocatib Study

We are testing a new medication, brensocatib, for adults with moderate to severe hidradenitis suppurativa. The study aims to see if it is more effective than a placebo in improving symptoms.

Hidradenitis Suppurativa1-2 yearsEfficacy phase (II)16-20 visitsInvestigational MedicinesCost ReimbursementPartially RemoteDermatology

Rheumatoid Arthritis: IMVT-1402 Treatment Study

We are evaluating a new treatment for adults with difficult-to-treat rheumatoid arthritis. The study aims to see if it helps improve symptoms compared to a placebo.

ACPA-Positive Rheumatoid Arthritis6-12 monthsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteRheumatology

Lung Cancer Treatment: Chemotherapy + Atezolizumab

We are studying a combination of chemotherapy and atezolizumab for patients with stage IIIA and IIIB non-small cell lung cancer. This trial aims to see if this approach improves survival and treatment outcomes before and after surgery.

Non-small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology